Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RA Capital
Biotech
Ramaswamy-backed Ambros launches with $125M to develop pain med
Ambros is using the money to fund a phase 3 trial of Abiogen's neridronate for Complex Regional Pain Syndrome type 1.
Angus Liu
Dec 16, 2025 1:32pm
Freenome to go public in $330M SPAC deal
Dec 5, 2025 10:35am
Triana crafts $120M series B to take glue degrader into clinic
Dec 3, 2025 10:35am
Artios Pharma widens clinical ambitions with $115M series D
Nov 17, 2025 8:00am
Electra shines with $183M fundraise for rare disease trial
Oct 22, 2025 8:26am
Sparrow flits forward with $95M for midstage diabetes asset
Sep 24, 2025 11:22am
